<DOC>
	<DOC>NCT02211157</DOC>
	<brief_summary>Study to assess safety, pharmacokinetics and pharmacodynamics of BIRB 796 BS in escalating multiple doses with and without a 64 g fat breakfast at the 50 mg dose level</brief_summary>
	<brief_title>Safety, Pharmacokinetics and Pharmacodynamics of BIRB 796 BS Tablets Administered to Healthy Human Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male subjects as determined by results of screening Signed written informed consent in accordance with Good Clinical Practice and local legislation Age ≥ 18 and ≤ 45 years Broca ≥ 20% and ≤ + 20% Any findings of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders Surgery of gastrointestinal tract (except appendectomy) History of orthostatic hypotension, fainting spells and blackouts Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders Chronic or relevant acute infections History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator Intake of drugs with a long halflife (&gt;24 hours) within 1 month prior to administration or during the trial) Use of any drugs which might influence the results of the trial within 10 days prior to administration or during trial Participation in another trial with an investigational drug within 2 months prior to administration or during trial Smoker (&gt; 10 cigarettes or 3 cigars or 3 pipes/day) Inability to refrain from smoking on study days Alcohol abuse (&gt; 60 g/day) Drug abuse Blood donation &gt; 400 ml within 1 month prior to administration or during the trial Excessive physical activities within 5 days prior to administration or during the trial Any laboratory value outside the reference range of clinical relevance including, but not limited to total white cell count ≥ 10 x 10**9/L, Creactive protein ≥ 4.5 mg/L, GammaGlutamyl Transferase ≥ 40 U/L, any hemoglobin or &gt; 15 mg/dl protein or urine dipstick, abnormal Multitest® assessment of cellular immunity History of any familial bleeding disorder Inability to comply with dietary regimen of study centre</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>